RAPT Therapeutics (RAPT) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Emission Environment Environmental Extreme Weather Intensity Life Cycle Materials Nature Offset Package Packaging Pandemic Toxic Access African American Asian Benefits Black California Consumer Privacy Act Community Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Demographics Disability Diversity Drug Pricing Employee Employee Retention Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Perquisites Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skills Social Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Workplace Safety Anti-corruption Assessment Assurance Attorney General Audit Bonus Bribery Chronic Classified Commitment Controversy Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Oversee Oversight Perquisite Pledging Purpose Quality Standard Recoup Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Sustainability Targets Tax Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 25, 2022, RAPT Therapeutics, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 11, 2022.

1.	Election of Directors

Director Name	Votes For	Votes Withheld	Broker Non-Votes

Michael Giordano, MD	22,848,997	1,545,121	1,787,483
Wendye Robbins, MD	22,920,508	1,473,610	1,787,483

The Class III director nominees were elected to hold office until the Company’s 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified.

2.	Ratification of Selection of Independent Registered Public Accounting Firm


Firm	Votes For	Votes Against	Abstentions
Ernst & Young LLP	26,178,293	1,370	1,938

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.